NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Centessa Pharmaceuticals reported Q1 2026 net loss of $79.2M and a Lilly acquisition agreement at $38 per share plus CVRs.
Centessa reported a Q1 2026 net loss of $79.2 million, or $(0.52) per share. Subsequent to quarter end, the company entered a transaction agreement for Lilly to acquire all shares for $38.00 cash plus contingent value rights up to $9.00 per share on milestones.
- Net loss $(79.2)M; loss per share $(0.52).
- Lilly acquisition announced March 31, 2026 at $38 + CVRs.
- Pipeline of asset-centric biotech programs.
- R&D spend drives quarterly loss.
- Transaction closing subject to court and regulatory approvals.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Forward outlook dominated by pending Lilly acquisition rather than standalone guidance.
Tailwinds
- Strategic acquisition premium for shareholders.
- Diversified pipeline assets.
Headwinds
- Large quarterly loss pre-deal.
- CVR milestones may not pay out.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2026
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro